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Michael J. Wannemuehler2, Bryan H. Bellaire2, Dennis W. Metzger4 & Balaji Narasimhan1
1Department of Chemical and Biological Engineering, Iowa State University, Ames, IA 50011, 2Department of Veterinary
Microbiology and Preventive Medicine, Iowa State University, Ames, IA 50011, 3Department of Materials Science and Engineering,
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NY 12208.
An opportunity exists today for cross-cutting research utilizing advances inmaterials science, immunology,
microbial pathogenesis, and computational analysis to effectively design the next generation of adjuvants
and vaccines. This study integrates these advances into a bottom-up approach for the molecular design of
nanoadjuvants capable of mimicking the immune response induced by a natural infection but without the
toxic side effects. Biodegradable amphiphilic polyanhydrides possess the unique ability to mimic pathogens
and pathogen associated molecular patterns with respect to persisting within and activating immune cells,
respectively. The molecular properties responsible for the pathogen-mimicking abilities of these materials
have been identified. The value of using polyanhydride nanovaccines was demonstrated by the induction of
long-lived protection against a lethal challenge of Yersinia pestis following a single administration ten
months earlier. This approach has the tantalizing potential to catalyze the development of next generation
vaccines against diseases caused by emerging and re-emerging pathogens.
O
ver the centuries, control of infectious diseases has often been hampered by the use of suboptimal tools
and a lack of knowledge to prevent the spread of epidemic and pandemic diseases, including a dearth of
efficacious vaccines. A transdisciplinary approach based on a new paradigm of immune activation is
needed to rationally design next generation adjuvants and vaccines. Typically, adjuvants fulfill three roles: 1) act
as a depot; 2) direct antigen to antigen presenting cells (APCs); and 3) induce co-stimulatory signals on APCs
necessary for activation of naı¨ve T cells. Unfortunately, current adjuvants approved for human use are often based
on off-the-shelf materials that were not originally intended for use as adjuvants and allow pathogens to evade host
defenses. The next generation of efficacious vaccines must incorporate adjuvants that can be tailored to generate
the optimal immune response that provides protection against the target pathogen. In this work, we describe a
bottom-up approach to design ‘‘pathogen-mimicking’’ nanoparticle adjuvants that has provided new insights
into the rational design of customized vaccine delivery vehicles to induce long-lived, protective immunity.
An ideal vaccine willmimic theway inwhich a naturally occurring infection induces a robust immune response
yet avoid the undesirable effects of disease1. Current approaches to enhance the efficacy of a vaccine with an
adjuvant often are designed to signal the innate immune system through a limited set of germ-line encoded
pattern-recognition receptors (PRRs). These receptors recognize a series of conserved pathogen-associated
molecular patterns (PAMPs)2. The design of non-toxic polymeric materials that activate APCs without deleteri-
ous side effects will lead to efficacious vaccine delivery systems while improving patient compliance by reducing
the need for prime-boost immunization regimen.
In this regard, degradable polymers are promising candidates for adjuvants and directed delivery vehicles
because their properties can be tailored to enhance the immune response3–5. While a number of degradable
polymer families (polyesters4, polyethers6, and polyphosphazenes7) have been investigated as vaccine adjuvants,
amphiphilic polyanhydrides offer a unique set of properties that allow them to function similarly to traditional
adjuvants but without the challenges associated with them (i.e., protein instability, low pH environments, poor
control over release kinetics, multiple dose immunization regimens, inclusion of surfactants, stabilizers, etc.)8.We
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have previously demonstrated that amphiphilic polyanhydride part-
icles release stable proteins in a controlledmanner9,10 while activating
APCs and inducing long-lived protective immunity in the absence of
additional excipients5,11–13.
Many chemistry-dependent interactions associated withmaterials
design have been evaluated, including protein stabilization, protein
release, and immune activation3,9–11,13, yet little work to date has
investigated the specific material properties responsible for these
attributes. The identification of these properties can lead to the
rational design of new and safe adjuvants that induce strong immune
responses reminiscent of natural infections. Fig. 1 depicts our hypo-
thesis that amphiphilic polyanhydride nanoparticles behave in a
manner that mimics the ability of pathogens to induce a robust
immune response. To test this hypothesis, we devised a transdisci-
plinary approach that combines polymer chemistry, cell biology,
immunology, and informatics analysis to identify the properties of
polyanhydrides that mimic microbial PAMPs. This approach pre-
sents a direct comparison between polyanhydride nanoparticles and
pathogens (i.e., Escherichia coli and Yersinia pestis) based on their
persistence within and ability to activate APCs. We analyzed the
ability of the nanoparticles to activate APCs in comparison to
lipopolysaccharide (LPS), a PAMP found on the outer membrane
of Gram-negative bacteria14. Using informatics analysis to evaluate
the interactions of APCs with polyanhydride nanoparticles (Fig. 1
left) or pathogens (Fig. 1 right), we have identified molecular attri-
butes that confer ‘‘pathogen-like’’ behavior to amphiphilic polyan-
hydrides. These insights were used to design and test a single dose
nanoparticle vaccine for pneumonic plague that induced long-lived
protection against a lethal challenge.
Results
In order to investigate internalization and persistence of nanoparti-
cles within APC, bone marrow-derived dendritic cells (DCs) were
incubated with fluorescently labeled polystyrene (PS) beads, 50:50
CPH:SA or 50:50 CPTEG:CPH polyanhydride nanoparticles, E. coli
or Y. pestis. The phagocytic capacity of DCs was assessed using
200 nm and 2 mm PS beads as an inert control. Morphometric ana-
lysis was utilized to assess particle/bacteria count as a function of size
to determine if the particles/bacteria changed in size (i.e., due to
aggregation or degradation) internalization. These morphometric
patterns are observed during bacterial internalization, replication
and intracellular persistence and can therefore be utilized as a com-
parison parameter to assess the pathogen mimicking characteristics
of nanoparticles. After 2 h, morphometric analysis revealed that the
different particle chemistries and the bacteria were similarly inter-
nalized by DCs with respect to particle size and the number of part-
icles (Fig. 2a and 2b). Microscopic observations at both 2 and 48 h
(Fig. 3a) indicated that the majority of particles were located within
late endosomes. These results are consistent with phagosome–
lysosome fusion events that are part of the exogenous pathway of
antigen uptake, processing, and presentation16.
The intracellular fate of pathogens (i.e., persistence, replication,
rapid degradation) influences the functional capacity of APCs. In
order to model the differential responses of the DCs induced by
the various treatments, we characterized the intracellular fate of
PS beads and polyanhydride nanoparticles, particularly in comparison
to that of bacteria. At 48 h, DCs incubated with PS beads contained
large numbers of individual (i.e., non-aggregating) particles (Fig. 3a).
In contrast, both 50:50 CPH:SA and 50:50 CPTEG:CPH nanopar-
ticles were found to be aggregated within lysosomes. More 50:50
CPTEG:CPH nanoparticles persisted within this intracellular com-
partment at 48 h (as evidenced by similar size versus number rela-
tionships) as compared to 50:50 CPH:SA nanoparticles (Fig. 3b).
Because both polyanhydride nanoparticle formulations degraded,
our hypothesis is that the amphiphilic 50:50 CPTEG:CPH nanopar-
ticles maintained their size because their degradation was balanced
Figure 1 | Cartoon representation of the hypothesis that polyanhydride nanoparticles mimic the immune activation capacity of pathogens. Molecular
structures dictate how materials are internalized and processed by APCs, which in turn leads to cellular activation. Utilizing informatics analysis, large
data sets can be mined to determine which nanoparticle chemistries (left) are able to best mimic pathogen-induced activation of APCs (right). Further
analysis with this approach allows for the identification of molecular descriptors that are specifically responsible for APC activation. Structures of 50:50
CPTEG:CPH (top left quadrant) and LPS (top right quadrant) were obtained as permitted15.
www.nature.com/scientificreports
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by their aggregation, whereas the intracellular aggregation of the hy-
drophobic 50:50 CPH:SA nanoparticles far exceeds their degradation
(Fig. 3b).
When phagocytic cells like DCs internalize pathogens, they create
intracellular particulate agglomerates after 48 h as observed in Fig. 3.
When compared toE. coli andY. pestis internalization (Figs. 2 and 3),
the amphiphilic 50:50 CPTEG:CPH nanoparticles appeared to
be similarly internalized and persisted at 2 and 48 h, respectively.
This persistence of the 50:50 CPTEG:CPH nanoparticles suggests
that the stimuli provided by these particles to activate DCs would
not rapidly wane, much like that provided by persisting and replic-
ating bacteria17. Indeed, comparing morphometric results between
intracellular bacteria and internalized 50:50 CPTEG:CPH nano-
particles (Fig. 3b) revealed similar persistence patterns. In contrast,
hydrophobic 50:50 CPH:SA nanoparticles aggregated over time,
resulting in larger but fewer particles.
Furthermore, lysosomal localization of the 50:50 CPTEG:CPH
nanoparticles provides an optimal location for antigen presentation
with concomitant cell activation18,19. It is of note that while the ma-
jority of the nanoparticles were found within Lamp11 lysosomes
at 48 h, a minor portion of intracellular particles were not, and could
be either within Lamp12 vesicles or, more likely, free within the
cytosol. The capacity for antigen release within both lysosomal
and cytosolic compartments could enable cross presentation and
enhanced antigen presentation – experiments to test this hypothesis
are currently underway in our laboratories.
Given the central role of DCs in the development of robust im-
mune responses, we next assessed the capacity of the polyanhydride
Figure 2 | Internalization of nanoparticles and bacteria (E. coli or Y. pestis) in dendritic cells at 2 h post-incubation. (a) Mouse DCs were incubated
separately with either fluorescently-labeled (green) PS beads (200 nm and 2.0 mm), 50:50 CPH:SA nanoparticles, 50:50 CPTEG:CPH nanoparticles, E.
coli, or Y. pestis. Fluorescent detection of phalloidin1 polymerized actin is shown in red. Photomicrographs shown are representative of results obtained
from five independent experiments (scale bars 5 5 mm). (b) Results were compiled from amorphometric analysis performed on replicate, epifluorescent
photomicrographs for each treatment group. For the morphometric analysis at 2 h, data points were ordered based on size (mm2) from smallest to largest
along the vertical axis and the total number of particles measured is reflected on the horizontal axis.
www.nature.com/scientificreports
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nanoparticles to activate DCs in comparison to LPS. DCs stimulated
with hydrophobic 50:50 CPH:SA nanoparticles failed to increase
surface expression of major histocompatibility complexes (MHC) I
and II and the T cell co-stimulatory molecules CD86 and CD40 over
non-stimulated DCs (Fig. 4a). In contrast, stimulation of DCs with
amphiphilic 50:50 CPTEG:CPH nanoparticles resulted in a signifi-
cant increase in all these activation markers over the non-stimulated
controls (Fig. 4a). Moreover, 50:50 CPTEG:CPH nanoparticles acti-
vated DCs to a similar degree as did treatment with LPS in terms of
MHC I, MHC II, and CD86 expression but not CD40 expression
(Fig. 4a). Significantly greater quantities of the pro-inflammatory
cytokines IL-6, IL-12p40, and TNF-a were secreted from DCs
exposed to 50:50 CPH:SA or 50:50 CPTEG:CPH nanoparticles as
compared to non-stimulated DCs; however, the amounts of cyto-
kines induced by nanoparticles were far less than those induced
by LPS (Fig. 4b). This data reveals a potential benefit of 50:50
CPTEG:CPH nanoparticles as a vaccine adjuvant, because excessive
CD40 signaling and pro-inflammatory cytokine production can lead
to adverse consequences. Indeed, mice deficient in CD40 are more
resistant to the effects of polymicrobial sepsis, produce less IL-6
and IL-12, and sustain less systemic organ damage than wild-type
controls20. Together, our data demonstrate that amphiphilic 50:50
CPTEG:CPH nanoparticles possess pathogen-like characteristics
that promote DC activation in a tempered context that would likely
limit the development of an overwhelming inflammatory response,
thus making them excellent vaccine delivery vehicles.
We then investigated the relationships between various polyanhy-
dride chemistries (represented by CPH:SA and CPTEG:CPH copo-
lymers),E. coli, Y. pestis, and LPS for intracellular persistence andDC
activation using a ‘‘blinded’’ approach to informatics analysis (Fig. 5).
Specifically, the trends in these relationships were quantitatively
modeled based on a set of molecular descriptors chosen to interrog-
ate pathogen-like behavior. The library of descriptors was built based
partially on the structural descriptors21 of CPH:SA and CPTEG:CPH
copolymers and microbial components (i.e., LPS) and on experi-
mentally measured descriptors such as glass transition temperature,
Figure 3 | Persistence of amphiphilic 50:50 CPTEG:CPH nanoparticles and bacteria (E. coli or Y. pestis) in dendritic cells at 48 h post-incubation.
(a) Fluorescent antibody detection of LAMP-11 lysosomes is shown in red. Photomicrographs shown are representative of results obtained from five
independent experiments (scale bars 5 5 mm). (b) See caption for Figure 2b).
www.nature.com/scientificreports
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Figure 5 | Informatics analysis using specific molecular descriptors to identify polymer chemistries that behave in a pathogen-like manner.
(a) Similarity (correlation) matrix for the paired comparison of LPS and various polyanhydride copolymers in terms of molecular descriptors; the red
color indicates highest similarity and blue represents lowest similarity with LPS. Based on Pearson’s correlation, 50:50 CPTEG:CPH showed the highest
similarity with LPS (indicated by the blue dotted circles). (b) In terms of intracellular persistence, 50:50 CPTEG:CPH nanoparticles are more pathogen-
like than 50:50 CPH:SA or PS. (c) In terms of DC activation, 50:50 CPTEG:CPH nanoparticles are more pathogen-like than 50:50 CPH:SA or NS.
(d) Using a PLSmodel linkingmolecular descriptors with the positions of the nanoparticle formulations in panel (b) representing the y-axis and panel (c)
representing the x-axis, the descriptors that influence pathogen-like behavior in terms of both nanoparticle persistence andDC activation were identified
(relevant descriptors labeled on figure).
Figure 4 | Polyanhydride nanoparticles generate an activatedDCphenotype similar to that ofDCs stimulated with LPS. Cell surfacemarker expression
(a) and cytokine secretion (b) for non-stimulated (NS, negative control) DCs, DCs stimulated with LPS (positive control) or nanoparticles composed of
either 50:50 CPH:SA or 50:50 CPTEG:CPH for 48 h. Aminimumof eight replicates was used per group. Error bars represent standard error.MFI5mean
fluorescence intensity. * indicates p # 0.002 compared to NS and # indicates p # 0.002 compared to LPS.
www.nature.com/scientificreports
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hydrophobicity, and erosion kinetics (Table 1 and Supplementary
Data Table 1). Thermal properties of LPS are known and correlate
closely with those of whole bacteria22,23. The chemical and structural
similarities between the polyanhydride chemistries and LPS were
explored using a correlation similarity metric24, where similarity
was defined by the proximity between chemistries in the descriptor
space. Of the polymer formulations evaluated, the similarity
plot shown in Fig. 5a demonstrates that the amphiphilic 50:50
CPTEG:CPH has the highest similarity with LPS.
Using principal component analysis (PCA), we identified the rela-
tionships between various polyanhydride formulations and patho-
gens or LPS in the context of intracellular persistence and DC
activation (Fig. 5b and 5c, respectively)25. An Euclidean geometrical
mapping metric that considers both the distance between two points
as well as the angle between point-origin-point was used to identify
similarity in the attributes associated with the targeted functionality
of pathogen-like behavior. For both intracellular persistence (Fig. 5b)
and DC activation (Fig. 5c) data, the angular direction of correlation
was drawn as an arrow and defined based on maximizing the differ-
ence between the target (i.e., LPS or bacteria) and the nanoparticle
formulations. The geometrical proximity of the angular projection
of the 50:50 CPTEG:CPH nanoparticle cluster to the target is closer
than that of the 50:50 CPH:SA nanoparticle cluster, suggesting
that the amphiphilic 50:50 CPTEG:CPH nanoparticles behave more
similarly to bacteria or LPS.
In addition, we developed predictive models via partial least
squares to connect experimental measurements with molecular
descriptors by predicting the PCA values of Figs. 5b and 5c as a
function of molecular descriptors. The combined results of the mod-
els are shown in Fig. 5d, where the horizontal axis represents DC
activation and the vertical axis represents intracellular persistence. In
both cases, the increasing positive value of a molecular descriptor
indicates increasing pathogen-like behavior. The specific descriptors
responsible for being pathogen-like in terms of DC activation and
intracellular persistence identified by our informatics methods are:
i) percentage of hydroxyl end groups, ii) hydrophobicity, iii) alkyl
ethers, iv) aliphatic carbons, and v) backbone oxygen moieties.
The concept of ‘similarity’ defined in terms of molecular des-
criptors and physicochemical properties is a valuable tool to screen
appropriate adjuvant candidates, enhancing our understanding
of the key molecular attributes responsible for optimal adjuvant
activity as well as pathogen-like behavior. For example, we identi-
fied hydroxyl end groups as an important molecular feature of the
50:50 CPTEG:CPH nanoparticles. When this polymer degrades, it
exposes numerous hydroxyl end groups. Identification of hydroxyl
end groups as a pathogen-like characteristic is consistent with the
structural components of LPS26 and may explain the observed sim-
ilarities in DC activation profiles (Fig. 4). Indeed, recent studies by
Hubbell and co-workers have shown that hydroxyl end groups on
nanoparticles significantly influenced complement activation and
subsequent DC trafficking to lymph nodes27. It is striking that
descriptors such as hydroxyl end groups, alkyl ethers, and backbone
oxygen moieties are commonly observed molecular constituents
on pathogens and that the same parameters were identified by
the (blinded) informatics analysis when complementary but dissim-
ilar experimental data (from microscopy and flow cytometry) were
compared.
Finally, we demonstrated the success of utilizing a pathogen-
mimicking nanoparticle vaccine to induce long-term protection
against pneumonic plague. Our previous studies have shown that
encapsulation of F1-V antigen into amphiphilic polyanhydride part-
icles preserved the antigenicity of F1-V upon release28. In this work,
we designed and tested three vaccine formulations based on 50 mg of
soluble F1-V (S50), S50 adjuvanted with 500 mg of blank 50:50
CPTEG:CPH nanoparticles (S50 1 E0), and 40 mg of soluble F1-V
and 10 mg of encapsulated F1-V in 500 mg of 50:50 CPTEG:CPH
Table 1 | Molecular descriptors (1–23) defined by Bicerano21 andmaterial property measurements (24–28) for the enumeration of polymer
and LPS features
ID Molecular descriptor Description
1 0x Atomic index 1
2 0xv Atomic index 2
3 1x Connectivity index 1
4 1xv Connectivity index 2
5 BB_index1 Backbone index 1
6 BB_index2 Backbone index 2
7 SG_index Backbone index 3
8 N_SP Number of atoms in the shortest path across the backbone of a polymeric repeat unit
9 N_C Number of carbon atoms
10 N_O Number of oxygen atoms
11 N_H Number of hydrogen atoms
12 N_ester Number of backbone -COO-
13 N_ether Number of -O- in a polymeric repeat unit
14 N_aromatic_ring Number of aromatic rings in a polymeric repeat unit
15 N_CH2 Number of CH2 groups in a polymeric repeat unit
16 N_alkyl_ether Number of ether (R-O-R’) linkages between two units R and R’ both of which are connected
to the alkyl carbon atom
17 N_nh Total number of non-hydrogen atoms in a repeat unit
18 Nmv 2*N_ester13*N_ether
19 N_K 23*(N_ether)23*N_acrylic_ester
20 N_rot Total number of rotational degrees of freedom parameter
21 N_dc 7*N_backbone_O112*N_side Group_O
22 N_group -N_alkyl_ether17*N_CO12*N_other C5O
23 MW Molecular weight
24 % OH end group Percentage of -OH groups
25 Hydrophobicity Water contact angle
26 % MW loss Percent loss of polymer molecular weight from NMR and GPC
27 % Erosion Percent of polymer eroded, from erosion kinetics experiments
28 Tg Glass transition temperature from DSC
www.nature.com/scientificreports
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nanoparticles (S40 1 E10). C57BL/6 mice were intranasally vacci-
nated with these formulations and subsequently challenged at 280
days post-vaccination with 1200 CFU of Y. pestis CO92. In these
experiments, none of the mice vaccinated with S50 or S50 1 E0 sur-
vived the challenge, whereas all the mice treated with the S40 1 E10
formulation survived (Fig. 6a). Protection from the lethal challenge
was strongly correlated with the F1-V-specific antibody titer and
antibody avidity. Mice vaccinated with either S50 1 E0 or S40 1 E10
generated significantly higher F1-V-specific antibody titers than ani-
mals vaccinated with S50 (Fig. 6b). However, by 6 weeks post-vac-
cination, anti-F1-V IgG titers began to wane in mice vaccinated with
S50 1 E0. In contrast, the F1-V-specific IgG titer in S40 1 E10 vacci-
nated mice was sustained for 275 days. In addition to antibody titer,
we evaluated avidity as a measure of the quality of the antigen-
specific antibody. As shown in Fig. 6c, mice vaccinated with either
S50 or S50 1 E0 formulations developed a low avidity F1-V-specific
IgG response. In contrast, mice vaccinated with S40 1 E10 generated a
higher avidity anti-F1-V specific IgG antibody by 3 weeks post-
vaccination that was sustained for 275 days. Together, the data in
Fig. 6 demonstrate that the pathogen-mimicking nanoparticle vac-
cine successfully protected animals against a lethal Y. pestis challenge
280 days after a single intranasal administration.
The ability to induce high titer antibody responses to F1-V fol-
lowing intranasal vaccination has been shown to be important for the
protection of mice against pneumonic Y. pestis infections29–31. Each
of these studies demonstrated the ability to induce high titer antibody
responses to F1 and/or V; however, high titer antibody responses did
not always correlate with protection. This suggests that the quality (i.e.,
avidity) of the antibody response may also be a critical factor in a
protective immune response. In this regard, the studies reported herein
have demonstrated that the use of a polyanhydride nanoparticle-
based vaccine induced long-lived, high titer, and high avidity anti-
F1-V antibody responses following a single intranasal vaccination.
Unlike the previous studies, these responses were induced without
the use of alum or TLR ligands. Similar to that induced by a natural
infection, the robustness of the immune response induced by a single
administration of the nanoparticles was remarkable in that complete
protection of mice from Y. pestis-induced pneumonia was observed for
at least 280 days post-vaccination.
Discussion
An ideal vaccine delivery system should consist of non-toxic materi-
als that mimic the immune enhancing capabilities of PAMPs and
activate APCs without deleterious side effects. Our results dem-
onstrate that by combining cell population-based and individual
cell-based analyses with informatics, the molecular properties
responsible for the ‘‘pathogen-mimicking’’ behavior of amphiphilic
nanoparticles can be identified. The ability to change size and shape
as a result of interacting with the cell, without being eliminated, was
best exhibited by the 50:50 CPTEG:CPH nanoparticles. This obser-
vation can be equated to the intracellular persistence and survival
of many microbial pathogens including Brucella, Salmonella, and
Mycobacterium species32. Moreover, the 50:50 CPTEG:CPH nano-
particles possessed the ability to enhance DC activation similar to
LPS without inducing a toxic cytokine storm. The informatics ana-
lysis confirmed the similarity between 50:50 CPTEG:CPH nano-
particles and bacteria/LPS and identified the molecular descriptors
responsible for their similarity in terms of intracellular persistence
and DC activation. Vaccination of mice with 50:50 CPTEG:CPH
nanoparticles administered as a single intranasal dose induced
high-titer and high-avidity antibody responses and 100% protection
against a liveY. pestis challenge for at least 280 days post-vaccination.
Our transdisciplinary approach to adjuvant design provides a tool-
box that can be used to rationally identify and design ‘‘pathogen-
mimicking’’ materials for use in combination vaccines that will
induce the appropriate immune modulation to protect against a wide
range of pathogens. We hypothesize that the insights gained by our
approach will elucidate important principles of rational design of
adjuvants. We foresee that the immunological and public health
challenges associated with the control of emerging and re-emerging
infectious diseases may not be met by the use of off-the-shelf adju-
vants and delivery systems that must be supplemented with TLR
ligands or excipients and administered multiple times to obtain
protection33. Instead, these challenges will likely require the develop-
ment of novel vaccine delivery platforms that appropriately modu-
late the immune response and improve patient compliance by
requiring only a single administration.
Methods
Materials. Carboxylic diacid monomer synthesis required the use of 1,
6-dibromohexane (98.5%), 4-hydroxybenzoic acid (96%), 1-methyl-2-pyrrolidinone
anhydrous (99.5%), triethylene glycol (99%) purchased from Sigma Aldrich
Figure 6 | Single administration of 50:50 CPTEG:CPH nanoparticle
vaccine provided complete protection against lethal Y. pestis challenge
and induced a long-lived, high-titer, high-avidity antibody response.
(a) C57BL/6 mice were challenged intranasally with 1200 CFU (LD100) Y.
pestis CO92 at 280 days post intranasal vaccination (n 5 526 per group).
(b) Kinetics of IgG antibody titer throughout 275 days post-vaccination
(n 5 6 per group). (c) Kinetics of IgG antibody avidity throughout 275 days
post vaccination (n 5 6 per group). Titer and avidity data are presented as
mean 6 SEM. For (a), # represents a statistically significant difference from
all other treatments at p # 0.0016 and for (b) and (c) * represents a
statistically significant difference from all other treatments at p # 0.05.
www.nature.com/scientificreports
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(St. Louis, MO); 4-p-fluorobenzonitrile (98%) purchased from Apollo Scientific
(Stockport, Cheshire, England); and sodium hydroxide, sulfuric acid, acetonitrile,
dimethyl formamide, toluene and potassium carbonate purchased from Fisher
Scientific (Fairlawn, NJ). Acetic anhydride, chloroform, petroleum ether, ethyl ether,
methylene chloride and hexanes were purchased from Fisher Scientific. DC culture
medium included RPMI 1640, HEPES buffer, L-glutamate, penicillin-streptomycin,
gentamycin acquired from Mediatech (Herndon, VA); heat inactivated fetal calf
serum acquired from Atlanta Biologicals (Atlanta, GA); and GM-CSF acquired from
PeproTech (Rocky Hill, NJ).Materials used in flow cytometry included fixative buffer
(BD Bioscience); mouse serum; anti-mouse CD16/32 FccR purchased from
eBioscience (San Diego, CA); b-mercaptoethanol and unlabeled rat immunoglobulin
purchased from Sigma Aldrich; E. coli lipopolysaccharide (LPS) was acquired from
Sigma Aldrich. FluoSpheresH (200 nm and 2 mm) were purchased from Invitrogen
(Carlsbad, CA). Y. pestis, strain CO92 (NR-641) and the Y. pestis F1-V fusion protein,
recombinant from E. coli (NR-4525), were obtained from the Biodefense and
Emerging Infections Repository (Manassas, VA).
Polymer Synthesis, Nanoparticle Fabrication, and Characterization. Sebacic acid
was purchased from Sigma Aldrich. Synthesis of CPTEG and CPH diacids, SA and
CPH pre-polymers, and CPH:SA and CPTEG:CPH copolymers was performed as
previously described34,35. The polymers were characterized using 1H nuclear magnetic
resonance spectroscopy, gel permeation chromatography, and differential scanning
calorimetry. All properties evaluated of the synthesized polymers were within
accepted ranges34,35.
Both FITC-dextran loaded and blank nanoparticles were fabricated using the
protocol reported in Ulery et al.13. The endotoxin levels of these particles were tested
using a Limulus Amebocyte Lysate (LAL) QCL-1000 test kit (Cambrex, Walkersville,
MD) as described previously12. The results indicated that the particles exhibited an
endotoxin content of less than 0.1 EU/mL, which is five times lower than the max-
imum level permitted by theUnited States FDA for new drugs tested by the LAL test36.
Nanoparticle morphology and size was investigated using scanning electron micro-
scopy (JEOL 840A, JEOL Ltd., Tokyo, Japan) and appeared to be spherical in shape.
The size of the 50:50 CPTEG:CPH nanoparticles was 206 6 47 nm and that of the
50:50 CPH:SA nanoparticles was 415 6 76 nm (data presented as mean 6 standard
deviation from three independent batches of nanoparticles). No differences in size or
morphology were found for blank or 1% FITC-dextran-loaded nanoparticles across
all chemistries.
Culture, Stimulation, and Analysis of C57BL/6 Dendritic Cells. All experiments
involving animals were carried out in accordance with procedures approved by
the Iowa State University Institutional Animal Care and Use Committee. The
dendritic cells (DCs) were prepared from bonemarrow cells isolated from the femurs,
tibias, humeri and ilia of C57BL/6mice (obtained fromHarlan Sprague Dawley). DCs
were cultured, stimulated and assessed for cell surface marker expression and
cytokine secretion as described previously with the same materials11. Nanoparticle
stimulation doses of 125 mg/mL and LPS stimulation doses of 200 ng/mL were
utilized.
Intracellular Localization. Intracellular localization of nanoparticles was compared
between PS beads at a 1:1000 dilution and 250 mg/mL of 1% FITC-dextran loaded
nanoparticles composed of either 50:50 CPH:SA or 50:50 CPTEG:CPH. DCs were
infected with green fluorescent protein (GFP)-expressing E. coli HB101 or Y. pestis
Dpgm at multiplicity of infection (MOI) of 100 and 10, respectively. Following nine
days of culture, DCs were pulsed with particles for 30 min (2 h sample) or 6 h (48 h
sample). E. coli andY. pestiswere incubated for 30 min and 48 hwith DCs. Cells were
subjected to immunofluorescence microscopy to observe time-dependent
intracellular trafficking of individual nanoparticles within DCs, similarly to previous
work13. Polymerized actin was labeled with Alexa 568 conjugated phalloidin
mushroom toxin (Molecular Probes-Invitrogen) and lysosomes were stained with
ID-4B anti-LAMP-1 (lysosomal-associated membrane protein 1). Epifluorescence
and immunofluorescence microscopy were performed using an inverted Olympus
FluoviewTM 1000 laser scanning confocal microscopy. Intracellular trafficking
analysis and final images were prepared using ImageJ v1.36b (NIH, Bethesda, MD)
loaded with particle counting algorithms.
Vaccinations and Challenge of Mice. Y. pestis CO92 was grown overnight at 37uC
in heart-infusion broth supplemented with 0.2% D-galactose. Eight-week-old female
C57BL/6 mice were obtained from the Jackson Laboratory (Bar Harbor, ME)
and maintained under SPF conditions. The Institutional Committees on Animal
Care and Use at either Iowa State University or Albany Medical College approved
all procedures involving animals. Mice were vaccinated and challenged and the
methods to measure antibody titer and avidity were performed as described
previously5.
Data and Statistical Analysis. JMP software (SAS Institute, Cary, NC) was used to
make comparisons between treatments and the negative (NS) control and the positive
(LPS) control using the student T-test.
Informatics Analysis. The similarity matrix shown in Fig. 5a was constructed with
the correlation (R) metric defined by the following equation:
R x,yð Þ~ cov x,yð Þ
sxsy
~
P
n
i~1 xi{xmeanð Þ yi{ymeanð ÞffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiP
n
i~1 xi{xmeanð Þ2
q ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiP
n
i~1 yi{ymeanð Þ2
q
Here, x and y refer to a block of chemistries (LPS, 20:80 CPTEG:CPH, 50:50
CPTEG:CPH, 20:80 CPH:SA, 50:50 CPH:SA, poly(CPTEG), poly(CPH), and
poly(SA)), cov(x,y) is the covariance between x chemistry and y chemistry, and s is
the standard deviation. Note that only molecular descriptors 1–25 and 28 from
Table 1 were used to generate this similarity matrix.
The PCA analysis for nanoparticle persistence (Fig. 5b) used count, total area, and
average size from epifluorescence microscopy data, while that for DC activation
(Fig. 5c) used MHC I, MHC II, CD40, CD86, IL-6, IL-12p40, and TNF-a data. PLS
regression connected the descriptor data set with the results of the PC analyses. By
projecting the data onto a high-dimensional hyperplane defined by PCA analysis of
training data, the impact of the descriptors on the property were identified, while
taking co-linearity into account37.
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